Andrew Huberman· PhD
contrast that with cardiovascular disease where you know you have this apob biomarker you you understand the pathophysiology of how it works you have drugs that Target it so you have a biomarker so you give somebody a drug that lowers apob you can measure apob that's a really important and obvious thing to be able to do and then you have clinical outcomes which is oh when you take a bunch of people in primary prevention it takes this long before you see an effect in secondary prevention it only takes this long to see an effect right different risk stratifications all these different things we don't have any of that for Alzheimer's disease